LadRx (OTCMKTS:CYTR – Get Rating) and MiNK Therapeutics (NASDAQ:INKT – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.
Earnings & Valuation
This table compares LadRx and MiNK Therapeutics' gross revenue, earnings per share and valuation.
Get LadRx alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LadRx | N/A | N/A | -$6.70 million | ($0.15) | N/A |
| MiNK Therapeutics | N/A | N/A | -$30.21 million | ($0.78) | -2.71 |
MiNK Therapeutics is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares LadRx and MiNK Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LadRx | N/A | -67.61% | -45.39% |
| MiNK Therapeutics | N/A | -168.94% | -78.30% |
Risk & Volatility
LadRx has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of -0.66, suggesting that its stock price is 166% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for LadRx and MiNK Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LadRx | 0 | 0 | 0 | 0 | N/A |
| MiNK Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
MiNK Therapeutics has a consensus target price of $7.00, indicating a potential upside of 231.75%.
Institutional & Insider Ownership
0.1% of LadRx shares are held by institutional investors. Comparatively, 1.4% of MiNK Therapeutics shares are held by institutional investors. 12.8% of LadRx shares are held by company insiders. Comparatively, 13.2% of MiNK Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
LadRx beats MiNK Therapeutics on 6 of the 9 factors compared between the two stocks.
About LadRx
(Get Rating)
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
About MiNK Therapeutics
(Get Rating)
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.